The issue is a combination of fresh issue of 65.52 lakh shares aggregating to Rs 44.55 crores and offer for sale of 3.12 lakh shares aggregating to Rs 2.12 crores. Ambey Laboratories IPO is a book built issue of Rs 46.68 crores.
Ambey Laboratories IPO opens for subscription on July 4, 2024 and closes on July 8, 2024. The allotment for the Ambey Laboratories IPO is expected to be finalized on Tuesday, July 9, 2024. Ambey Laboratories IPO will list on NSE SME with tentative listing date fixed as Thursday, July 11, 2024.
Ambey Laboratories IPO price band is set at ₹65 to ₹68 per share. The minimum lot size for an application is 2000 Shares. The minimum amount of investment required by retail investors is ₹136,000. The minimum lot size investment for HNI is 2 lots (4,000 shares) amounting to ₹272,000.
Fast Track Finsec Pvt Ltd is the book running lead manager of the Ambey Laboratories IPO, while Link Intime India Private Ltd is the registrar for the issue. The market maker for Ambey Laboratories IPO is Nikunj Stock Brokers.
Refer to Ambey Laboratories IPO RHP for detailed information.
About Ambey Laboratories Limited
Ambey Laboratories, incorporated in 1985, manufactures agrochemical products for crop protection. The company has been serving the agrochemical sector for almost four decades.
The company manufactures and supplies 2,4-D base chemicals.
The company’s manufacturing facility in Behror, Rajasthan, is certified with ISO 9001:2015 by the Quality Research Organization and ISO 14001:2015 by the United Accreditation Foundation.
The company currently produces the following products for its customer base, which includes large corporates like Aromatic Rasayan Private Limited, JR Jindal Infraprojects Private Limited, and SC Formulator Co. Ltd:
- 2,4-D Acid 98% TC
- 2,4-D Sodium 95% SP
- 2,4-D Amine 866 | 720 | 480g/l SL
- 2,4-D Ethyl Hexyl Ester 96% TC
- 2,4-D Ethyl Ester 96% TC
- Chlorpyriphos 97%TC / 20%EC / 50%EC
- Thiamethoxam 96%TC / 25%WG / 75%SG
- Pretilachlor 95%TC / 50%EC / 37%EW
- Metribuzin 97%TC / 70%WS
- Hexaconazole 92%TC / 5%SC / 5%EC / 10%EC
- Metalaxyl 98%TC / 35%WS
As of October 31, 2023 the company employs 220 people in various departments.
Ambey Laboratories IPO Details
| IPO Date | July 4, 2024 to July 8, 2024 |
| Listing Date | [.] |
| Face Value | ₹10 per share |
| Price Band | ₹65 to ₹68 per share |
| Lot Size | 2000 Shares |
| Total Issue Size | 6,864,000 shares(aggregating up to ₹46.68 Cr) |
| Fresh Issue | 6,552,000 shares(aggregating up to ₹44.55 Cr) |
| Offer for Sale | 312,000 shares of ₹10(aggregating up to ₹2.12 Cr) |
| Issue Type | Book Built Issue IPO |
| Listing At | NSE SME |
| Share holding pre issue | 18,688,819 |
| Share holding post issue | 25,240,819 |
| Market Maker portion | 312,000 shares |
Ambey Laboratories IPO Timeline (Tentative Schedule)
Ambey Laboratories IPO opens on July 4, 2024, and closes on July 8, 2024.| IPO Open Date | Thursday, July 4, 2024 |
| IPO Close Date | Monday, July 8, 2024 |
| Basis of Allotment | Tuesday, July 9, 2024 |
| Initiation of Refunds | Wednesday, July 10, 2024 |
| Credit of Shares to Demat | Wednesday, July 10, 2024 |
| Listing Date | Thursday, July 11, 2024 |
| Cut-off time for UPI mandate confirmation | 5 PM on July 8, 2024 |
Ambey Laboratories IPO Lot Size
Investors can bid for a minimum of 2000 shares and in multiples thereof. The below table depicts the minimum and maximum investment by retail investors and HNI in terms of shares and amount.| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 2000 | ₹136,000 |
| Retail (Max) | 1 | 2000 | ₹136,000 |
| HNI (Min) | 2 | 4,000 | ₹272,000 |
Ambey Laboratories IPO Reservation
| Investor Category | Shares Offered |
|---|---|
| QIB Shares Offered | Not more than 50% of the Net Issue |
| Retail Shares Offered | Not less than 35% of the Net Issue |
| NII (HNI) Shares Offered | Not less than 15% of the Net Issue |
Ambey Laboratories IPO Promoter Holding
The promoters of the company are Archit Gupta, Arpit Gupta, Sarina Gupta and Rishita Gupta.| Share Holding Pre Issue | 94.97% |
| Share Holding Post Issue |
Ambey Laboratories Limited Financial Information (Restated)
| Period Ended | 31 Jan 2024 | 31 Mar 2023 | 31 Mar 2022 | 31 Mar 2021 |
| Assets | 8,620.84 | 5,761.85 | 5,592.94 | 4,461.80 |
| Revenue | 10,043.69 | 10,743.47 | 8,511.19 | 8,241.54 |
| Profit After Tax | 607.73 | 456.93 | 357.47 | 1,033.67 |
| Net Worth | 3,431.34 | 2,363.60 | 1,906.67 | -786.39 |
| Reserves and Surplus | 1,562.46 | 588.66 | 131.73 | -1,275.74 |
| Total Borrowing | 2,005.44 | 1,365.22 | 1,804.86 | 3,292.98 |
Key Performance Indicator
The market capitalization of Ambey Laboratories IPO is Rs 171.64 Cr.KPI as of January 31, 2024.
| KPI | Values |
|---|---|
| ROE | 20.80% |
| ROCE | 13.14% |
| Debt/Equity | 0.58 |
| RoNW | 20.80% |
| P/BV | 3.58 |
| PAT Margin (%) | 6.01 |
| Post IPO | Pre IPO | |
|---|---|---|
| EPS (Rs) | 2.44 | 2.89 |
| P/E (x) | 27.81 | 23.54 |
Note:
- The Pre IPO EPS is calculated based on Pre issue shareholding as on date of RHP and the latest FY earnings as of March 31, 2023 that is available in RHP.
- The Post Issue EPS is calculated based on the Post issue shareholding and annualized FY earnings of January 31, 2024 that is available in RHP.
Objects of the Issue (Ambey Laboratories IPO Objectives)
The company intends to utilize the Net Proceeds for the following objects:
- To meet Working Capital Requirements
- General corporate purposes
- Issue related expenses
Ambey Laboratories Limited Contact Details
Ambey Laboratories Limited
Ground Floor, Property No.555 Tarla Mohalla,
Ghitorni, West Delhi
New Delhi, -110030
Phone: 0124-4000788
Email: cs@ambeylab.com
Website: http://www.ambeylab.com/ Read More-Emcure Pharmaceuticals Limited IPO (Emcure Pharma IPO) Detail
